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Urinary tract infection (UTI) is one of the most common infections 
that occurs during pregnancy. If left untreated, it could lead to 
significant maternal and perinatal morbidity and mortality.[1-3] It 
may be symptomatic or asymptomatic, which often makes diagnosis 
difficult. In a large number of patients, UTIs are preceded by 
asymptomatic bacteriuria (ASB).[1,4-6] Bacteriuria during pregnancy 
is associated with a low birthweight and premature delivery if left 
untreated.[7] 
The varying prevalence of UTI in pregnancy has been reported 
worldwide, ranging from 2% to 10%.[8] Some studies in the UK 
have shown that the incidence of ASB in pregnant women ranges 
from 2% to 5%.[9,10] However, the incidence of acute cystitis was 
more difficult to determine, as most women are treated empirically 
without culture being performed routinely.[8] Studies conducted in 
developing countries have shown that UTI often presents during the 
first antenatal visit and <1% develop bacteriuria following a negative 
screening in early pregnancy.[8] The treatment of ASB in pregnancy 
decreases the rate of persistent bacteriuria and the subsequent risk of 
developing pyelonephritis.[1] Based on this, screening for and treating 
of ASB in high-income countries are considered standard obstetrical 
care.[1] However, in South Africa (SA) and other resource-limited 
countries, the cost of standard urine culture is a limiting factor for 
generalised urine screening. Therefore, other more economical 
screening methods have been proposed, e.g. urine dipsticks, which 
is the recommended antenatal screening method in the SA public 
sector.
During pregnancy, significant physiological changes of the 
urogenital tract occur, which could increase the risk of pathogenic 
colonisation.[10] Detrusor tone decreases, bladder volume increases, 
and a majority of pregnant women develop ureteric dilatation 
owing to a combination of pressure from an expanding uterus and 
progestogenic relaxation of ureteric smooth muscle. This ultimately 
leads to urine stasis and vesico-ureteral reflux, which facilitates 
bacterial colonisation and ascending infection.[10]
Organisms that cause UTI in pregnant and non-pregnant patients 
are similar.[10] These organisms are usually from normal vaginal, 
perineal and faecal flora.[8] Common organisms include Escherichia 
coli, Staphylococcus aureus, Enterococcus faecalis, Proteus mirabilis, 
Klebsiella pneumoniae and group B streptococcus (GBS), among 
other less common organisms.[8] Vaginal colonisation with GBS 
is strongly associated with preterm rupture of membranes, labour 
and delivery and is a well-established cause of neonatal sepsis.[10] 
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Background. Urinary tract infection (UTI) is one of the most common infections during pregnancy, which can lead to significant maternal 
and perinatal morbidity and mortality if left untreated. Challenges when treating UTIs in pregnancy include fetal protection and resistance 
development of uropathogens. Currently, the Essential Medicines List recommends nitrofurantoin to treat cystitis and ceftriaxone to treat 
pyelonephritis in pregnant women. 
Objectives. To determine common pathogens causing UTI in pregnancy and their antibiotic susceptibility patterns. 
Methods. A retrospective analysis was performed of laboratory data for positive urine specimens from obstetric departments of 6 KwaZulu-
Natal Province hospitals during 2011 - 2016. Identification and susceptibility testing were performed using the VITEK 2 system. Results 
were interpreted according to the breakpoints of the Clinical and Laboratory Standards Institute, USA. 
Results. From 5 971 positive urine specimens, the most common isolate was Escherichia coli (n=3  236; 54.2%), followed by Klebsiella 
pneumoniae (n=770; 12.9%). Group B streptococcus (GBS) (n=239; 4.0%) and Enterococcus faecalis (n=251; 4.2%) were the most common 
Gram-positive pathogens. E. coli displayed significant resistance to trimethoprim-sulfamethoxazole (65.1%), cephalothin (38.3%), 
cefuroxime (27.3%), ciprofloxacin (16.9%) and amoxicillin-clavulanic acid (17.1%). Resistance to ceftriaxone and nitrofurantoin remained 
low ‒ 9.1% and 7.7%, respectively. Among Gram-positive pathogens, GBS displayed 100% penicillin susceptibility and E. faecalis showed 
92.9% susceptibility to ampicillin. 
Conclusions. E. coli is unsurprisingly the most common cause of UTI in pregnancy in KwaZulu-Natal. Susceptibility to ceftriaxone and 
nitrofurantoin remains good. Among Gram positives, GBS is prevalent and susceptible to penicillin, while E. faecalis is susceptible to 
ampicillin. As antimicrobial resistance evolves, routine surveillance is necessary to modify recommended empirical antibiotic use. 
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Therefore, diagnosing and appropriately 
treating patients who are infected with these 
organisms are of paramount importance.
The development of resistance to 
previously effective antibiotics by common 
uropathogens has been reported globally 
in the past few years.[7,11,12] Antibiotic 
suscep tibility patterns vary geographically, 
as well as in time.[7] Determining the 
common pathogens associated with UTIs in 
pregnancy and their antibiotic susceptibility 
patterns potentially reduces inappropriate 
antibiotic prescription and therefore 
develop ment of resistance.[7] Furthermore, 
detecting the changing susceptibility pattern 
of uropathogens against commonly used 
and recommended antibiotics, will be an 
effective strategy for empirical therapy.[7,13]
In SA, the National Department of 
Health publishes a Standard Treatment 
Guideline (STG) and Essential Medicines 
List (EML), which aim to provide clear 
guidance to healthcare workers regarding the 
management of all patients at primary care 
level.[14] Currently, the EML recommends 
nitrofurantoin to treat cystitis and ceftriaxone 
for pyelonephritis in pregnant women. 
Despite these recommendations, there is a 
paucity of data on the organisms isolated 
from pregnant women and the antimicrobial 
susceptibility profiles. This study was 
therefore conducted to evaluate the common 
bacterial causes of UTI in pregnancy, as well 
as the antibiotic susceptibility patterns of the 
uropathogens.
Methods
We conducted a retrospective analysis of 
laboratory reports for all positive urine 
specimens submitted from the obstetric 
departments of 6 public sector hospitals 
in Durban, KwaZulu-Natal Province, SA, 
during 2011 - 2016. Data were extracted 
from the local laboratory information 
system (TrakCare, SA), collated and 
reviewed. Duplicate results were excluded to 
reduce over-representation of any particular 
susceptibility pattern.
Isolates were identified by an automated 
VITEK 2 system (bioMérieux, France) and 
susceptibility testing was performed using 
the same system. Drugs tested for Gram-
negative bacteria were ampicillin/amoxi -
cillin, first-generation cephalosporins (e.g. 
cephalothin), second-generation cephalo -
sporins (e.g. cefuroxime), third-generation 
cephalosporins (e.g. ceftriaxone), nitrofu-
rantoin, nalidixic acid, amoxicillin-clavulan-
ic acid, ciprofloxacin, gentamicin, amikacin, 
trimethoprim-sulfamethoxazole and the 
carbapenems. Antibiotics tested for Gram-
positive bacteria were penicillin, ampicillin/
amoxicillin and vancomycin. The antibiotic 
susceptibility testing results were interpreted 
according to the Clinical and Laboratory 
Standards Institute (CLSI) breakpoints for 
the corresponding year.[15]
Data analysis
Simple data analysis based on the laboratory 
database was performed. Numerator and 
denominator were calculated as the number 
of uropathogens isolated and total number 
of organisms isolated in the urine specimens 
of pregnant women presenting with UTI, 
respectively, during the study period. The 
prevalence rate is a proportion and has been 
expressed as a percentage. The susceptibility 
rate was measured in a similar manner and 
was expressed as a percentage.
Ethical approval
Ethical approval was granted by the Research 
Ethics Committee, University of KwaZulu-
Natal (ref. no. BE085/12).
Results
Urine specimens with positive microbiologi-
cal cultures from 5 971 pregnant patients 
were received during the 6-year period. The 
most common organism isolated was E. coli 
(n=3 236; 54.2%), followed by K. pneumoniae 
(n=770; 12.9%). Other Gram-negative organ-
isms, including P. mirabilis, accounted for 
only 620 (10.4%) specimens. Among the 
Gram-positive organisms, E. faecalis and GBS 
were the most common organisms isolated 
(n=251; 4.2% and n=239; 4.0%, respectively). 
Other Gram positives accounted for only 
2.4%. Interestingly, the yeasts, Candida albi-
cans and Candida species, were relatively 
common organisms isolated (6.8% and 5.2%, 
respectively) (Fig. 1).
Table 1 shows the susceptibility of the 
commonly used antibiotics to treat UTI in 
pregnancy. E. coli displays a susceptibility of 
34.9% to trimethoprim-sulfamethoxazole. 
Susceptibility to the first- and second-
genera tion cephalosporins is 61.7% and 
72.7%, respectively. Amoxicillin-clavulanic 
acid and ciprofloxacin have a susceptibility 
of marginally >80%. Nitrofurantoin (for 
treating cystitis in pregnancy) and the third-
generation cephalosporins have a susceptibility 
pattern of >90%.
Table 2 shows the susceptibility of Gram-
positive uropathogens to the commonly 
used antibiotics. E. faecalis displays 93% 
Table 1. Susceptibility of Escherichia coli to commonly used antibiotics
Antibiotic
                 Escherichia coli
Total, n Susceptible, n (%)
Cephalothin/cephalexin 1 369 844 (61.7)
Amoxicillin-clavulanic acid 2 865 2 376 (82.9)
Cefuroxime 3 253 2 366 (72.7)
Ceftriaxone/cefotaxime 2 663 2 419 (90.8)
Trimethoprim-sulfamethoxazole 2 381 832 (34.9)
Nitrofurantoin 2 927 2 701 (92.3)




















Fig. 1. Frequency of organisms in urine specimens, 2011 - 2016.
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susceptibility to ampicillin/amoxicillin (the 
recommended antibiotic), and GBS is 100% 
susceptible to penicillin. The susceptibility 
to amoxicillin-clavulanic acid is similar, with 
almost 93% susceptibility for E. faecalis and 
100% susceptibility for GBS.
Susceptibility of E. coli to amoxicillin-
clavulanic acid, cefuroxime, ceftriaxone, 
nitrofurantoin and ciprofloxacin remained 
consistent over a 6-year period (Fig. 2). A 
general decline in susceptibility to these 
antibiotics was observed between 2015 and 
2016, with the exception of nitrofurantoin, 
which remained consistent. Trimethoprim-
sulfamethoxazole also remained consistent 
over the 6 years, demonstrating a suscepti-
bility pattern consistently lower than that for 
the other antibiotics tested.
Line graph values are shown in Table 3.
Discussion
This study was conducted to determine 
the common bacterial causes of UTI in 
pregnancy and to review the susceptibility 
pattern of drugs that can be used to treat 
this infection. Data from 6 years revealed 
E. coli as the most common uropathogen, 
accounting for 54.2% of pregnant patients in 
KwaZulu-Natal. This is in keeping with other 
studies conducted in both developing and 
developed countries, where E. coli was found 
in 35 - 82% of cases.[1,16-19] K. pneumoniae 
was the second most common organism 
isolated in the urine of obstetric patients, 
although it was significantly less common 
than E. coli (54.2% v. 12.9%). Among the 
Gram-positive organisms, E. faecalis and 
GBS were the most common organisms 
isolated (4.2% and 4.0%, respectively). In a 
study by Ulett et al.,[20] GBS bacteriuria during 
pregnancy occurred at a rate of 1 - 3.5%. 
Another study showed a prevalence of 0.4 - 
5% GBS bacteriuria in pregnancy.[21] In this 
study, GBS accounted for 4.0% of all isolates 
in obstetric patients, which is in keeping 
with the literature. Interestingly, Candida 
featured prominently (12% collectively), and 
its significance needs further analysis. With 
E. coli being the predominant uropathogen 
detected in this study, which was in keeping 
with the literature, the susceptibility pattern 
of antimicrobials was analysed against this 
organism.
A general decline in susceptibility to the 
majority of relevant antimicrobials tested was 
noted in the last 2 years of the study period. 
This is of increasing concern owing to the 
already limited options for antimicrobial use 
in obstetrics and requires close monitoring 
and surveillance. Decreasing susceptibility 
to the cephalosporins and co-amoxicillin-
clavulanic acid is especially important, as 
these antibiotics are frequently administered 
in pregnancy.[14] Ceftriaxone in particular 
is the antibiotic recommended in the EDL 
for severe UTI.[14] It is, however, important 
to note that this antibiotic maintained a 
susceptibility of >90% to E. coli during the 
first 5 years of the study, with a decline to 
83.3% in the last year. 
First-generation cephalosporins, e.g. 
cepha lo thin/cephalexin, are also very 
important drugs used in the treatment 
of UTI. Unfortunately, a disappointing 
susceptibility of 61.7% was shown for E. coli 
during the analysis period. Considering the 
safety of this antibiotic during pregnancy, as 
Table 2. Gram-positive uropathogens
Antibiotic
          Enterococcus faecalis        Group B streptococci
Total, n Susceptible, n (%) Total, n Susceptible, n (%)
Penicillin/ampicillin 168 144 (85.7) 221 221 (100)
Amoxicillin/ampicillin 240 223 (92.9) 148 148 (100)













Escherichia coli sensitivity over time















Fig. 2. Susceptibility of Escherichia coli over 6 years.
Table 3. Line graph values for susceptibility of Escherichia coli over 6 years (Fig. 2)
                                                            Year, %
Antibiotic 2011 2012 2013 2014 2015 2016
Cephalothin/cephalexin - - - - 91.7 -
Amoxicillin-clavulanic acid 83.2 80.9 82.4 84.8 85.6 80.5
Cefuroxime 87.7 91.1 88.3 86.9 87.1 78.4
Ceftriaxone/cefotaxime 94.2 92.8 93.8 91.8 90.2 83.3
Trimethoprim-sulfamethoxazole 25.8 30.1 35.3 37.6 34.2 38.6
Nitrofurantoin 92.0 91.9 90.6 91.8 94.0 93.7
Ciprofloxacin 84.8 84.7 85.8 82.8 82.5 78.3
875       September 2020, Vol. 110, No. 9
RESEARCH
well as its relatively low cost compared with other available antibiotics, 
it has been a useful alternative to other more expensive antibiotics. 
This was especially important during the period when nitrofurantoin 
(recommended for cystitis in pregnancy) had become unavailable 
owing to cessation of local production.[22] However, this susceptibility 
pattern may be unreliable, as the testing of nitrofurantoin was not 
consistent in the participating laboratories, and therefore these results 
may not be a true reflection of the actual susceptibility to this drug. 
Even though E. coli showed an increase in susceptibility to 
trimethoprim-sulfamethoxazole during the last 2 years of the study, 
it remains irrelevant because of its low susceptibility pattern of 25 - 
36.8% over the study period of 6 years and because it is no longer 
recommended in SA and many other countries globally for the 
treatment of UTI.[22-24] A resistance rate of 20% had previously been 
recommended as the threshold to avoid treatment with trimethoprim-
sulfamethoxazole.[23,24] The same study also indicates that this 
antimicrobial may remain effective at a clinical cure rate of 85%, 
even when the resistance rate is 30%.[23] However, insufficient data 
are available to determine whether the likelihood of failure due to the 
resistance levels outweighs the benefits of other antimicrobials that 
are used to treat UTI.[22] Data from our study show a consistently low 
susceptibility to trimethoprim-sulfamethoxazole, and considering 
the availability of other potential antibiotics in our setting, this drug 
has gradually lost its use in the treatment of UTI.
Nitrofurantoin, a urinary antiseptic agent, has maintained a 
susceptibility pattern of >90% (average 92.3%) over the 6-year 
study period. This is encouraging, as the drug still remains the 
recommendation for cystitis in pregnancy.[14] It has been suggested 
that the sustained susceptibility of E. coli to nitrofurantoin is due to its 
limited impact on the normal gut flora and thus limited selection of 
resistant organisms.[22,25] Various studies have demonstrated increased 
susceptibility of nitrofurantoin to uropathogens in pregnant women 
with or without UTI.[8,26,27] Consequently, use of this drug as first-
line treatment for cystitis has been recommended in these studies. 
Nitrofurantoin achieves a high urine concentration, but does 
not penetrate the renal parenchyma very well; therefore, it is 
not recommended in the treatment of pyelonephritis.[28] Some 
reports indicate that nitrofurantoin can be associated with a risk of 
neonatal haemolytic anaemia if the mother has glucose-6-phosphate 
dehydrogenase (G6PD) deficiency; it is, therefore, advised that this 
drug should be used with caution.[2,29,30] 
Decreasing susceptibility to fluoroquinolones (ciprofloxacin) 
in all of the laboratories is also of concern, as these are first-
line drugs recommended internationally[22,23,31] and in the EDL. 
However, the use of fluoroquinolones is essentially contraindicated 
during pregnancy owing to reports of fetal cartilage-development 
disorders.[2,32] However, a systematic review of prospective, controlled 
studies showed that the use of fluoroquinolones during the first 
trimester of pregnancy does not appear to be associated with an 
increased risk of major malformations after birth, stillbirths, preterm 
births or low birthweight.[2,33] Also, in the maternal care guidelines 
(National Department of Health), ciprofloxacin is recommended 
as an alternative agent in cases of penicillin allergy.[34] More data 
are needed to establish the safety of fluoroquinolones in pregnancy 
before prescribing or recommending their routine use.
Significantly less Gram-positive organisms than Gram-negative 
uropathogens were isolated (10% v. 90%). E. faecalis and GBS were 
the most common Gram-positive organisms isolated (n=251; 4.2% 
and n=239; 4.0%, respectively). Other Gram positives accounted for 
only 2.4%. GBS maintains its 100% susceptibility to penicillin, the 
drug of choice for this organism, which is in keeping with various 
other studies in the literature.[35,36] E. faecalis has a susceptibility 
pattern of almost 90% to ampicillin/amoxicillin, the recommended 
antibiotic for this organism.[37] As a result, the data show that these 
drugs are the recommended drugs of choice in the treatment of UTI 
caused by the abovementioned organisms.
Study limitations
This study has various limitations. As it is laboratory based, we 
could not distinguish between community- and hospital-acquired 
infections. Furthermore, the request for a urine culture is clinician 
dependent; therefore, there may be bias in the selection of patients 
who require urine cultures. There were insufficient data on first-
generation cephalosporins from all the participating sites, which 
could significantly affect the recommendations for the treatment of 
UTI. There was possible bias in the data because of the discordant 
reporting of antibiotics in the intermediate susceptible range as 
resistant. Isolates from urine specimens with minimum inhibitory 
concentration values that fall between susceptible and resistant 
breakpoints, may be susceptible because elevated levels of the drug 
can be achieved through concentration in the urine. 
Finally, from this analysis, it can be recommended that nitrofurantoin 
should be used in the treatment of cystitis in pregnancy and 
ceftriaxone for pyelonephritis. The other recommended antibiotics 
may also be used, with an awareness of increasing resistance, and 
the possibility of considering requesting susceptibility testing. As the 
treatment of UTI is usually empirical, the possibility of treatment 
failure increases as the levels of resistance increase, and local choices 
for empirical therapy become restricted.[22] In view of the increasing 
resistance to commonly used antimicrobials, we may expect an 
increasing need for culture and susceptibility testing. It would be 
important to review whether this is the case in future studies. As drug 
resistance is evolving, routine surveillance is necessary to provide 
updated information on recommended antibiotic use.
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4. Matuszkiewicz-Rowińska J, Małyszko J, Wieliczko M. Urinary tract infections in pregnancy: Old and 
new unresolved diagnostic and therapeutic problems. Arch Med Sci 2015;11(1):67-77. https://doi.
org/10.5114/aoms.2013.39202
5. Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: An 18-year retrospective 
analysis. Am J Obstet Gynecol 2014;210(3):1-6. https://doi.org/10.1016%2Fj.ajog.2013.10.006
6. Sheffield JS, Cunningham FG. Urinary tract infection in women. Obstet Gynecol 2005;106(5):1085-1092. 
https://doi.org/10.1097%2F01.aog.0000185257.52328.a2
7. Sibi G, Kumari P, Kabungulundabungi N. Antibiotic sensitivity pattern from pregnant women with 
urinary tract infection in Bangalore, India. Asian Pac J Trop Med 2014;7(Suppl 1):S116-S120. https://
doi.org/10.1016%2Fs1995-7645%2814%2960216-9
876       September 2020, Vol. 110, No. 9
RESEARCH
8. Onoh R, Umeora O, Egwuatu V, et al. Antibiotic sensitivity pattern of uropathogens from pregnant 
women with urinary tract infection in Abakaliki, Nigeria. Infect Drug Resist 2013;6:225-233. https://
doi.org/10.2147%2Fidr.s46002
9. National Antibiotic Surveillance. Surveillance forum ‒ private susceptibility data ‒ July - December 
2007. S Afr J Epidemiol Infect 2008;23(2):44-48. https://doi.org/10.1080%2F10158782.2008.11441312
10. McCormick T, Ashe RG, Kearney PM. Urinary tract infection in pregnancy. Obstet Gynaecol 
2008;10(3):156-162. https://doi.org/10.1576%2Ftoag.10.3.156.27418
11. Shigemura K, Tanaka K, Adachi M, et al. Chronological change of antibiotic use and antibiotic 
resistance in Escherichia coli causing urinary tract infections. J Infect Chemother 2011;17(5):646-651. 
https://doi.org/10.1007%2Fs10156-011-0241-2
12. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of 
uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001;135(1):41-50. 
https://doi.org/10.7326%2F0003-4819-135-1-200107030-00012
13. Khan S, Rashmi S, Singh P, et al. Pregnancy-associated asymptomatic bacteriuria and drug 
resistance. J Taibah Univ 2015;10(3):340-345. https://doi.org/10.1016%2Fj.jtumed.2015.01.011
14. National Department of Health. Standard Treatment Guideline and Essential Medicine List for South 
Africa. Primary Health Care Level. Pretoria: NDoH, 2018. 
15. Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility 
Testing. M100-S21-26. Pennsylvania, USA: CLSI, 2017. 
16. Farkash E, Weintraub AY, Sergienko R, et al. Acute antepartum pyelonephritis in pregnancy: A critical 
analysis of risk factors and outcomes. Eur J Obstet Gynaecol Reprod Biol 2012;162(1):24-27. https://
doi.org/10.1016%2Fj.ejogrb.2012.01.024
17. Oladeinde BH, Omoregie R, Oladeinde OB. Asymptomatic urinary tract infection among pregnant 
women receiving ante-natal care in a traditional birth home in Benin city, Nigeria. Ethiop J Health Sci 
2015;25(1):3. https://doi.org/10.4314%2Fejhs.v25i1.2
18. MacLean AB. Urinary tract infection in pregnancy. Int J Antimicrob Agents 2001;17(4):273-277. 
https://doi.org/10.1016%2Fs0924-8579%2800%2900354-x
19. Unlu B, Yildiz Y, Keles I, et al. Urinary tract infection in pregnant population, which empirical 
antimicrobial agent should be specified in each of the three trimesters? Ginekol Pol 2014;85(5):371-376. 
https://doi.org/10.17772%2Fgp%2F1744
20. Ulett KB, Benjamin Jr WH, Ulett GC, et al. Diversity of group B streptococcus serotypes 
causing urinary tract infection in adults. J Clin Microbiol 2009;47(7):2055-2060. https://doi.
org/10.1128%2Fjcm.00154-09
21. Allen VM, Yudin MH. Management of group B streptococcal bacteriuria in pregnancy. J Obstet 
Gynaecol Can 2018;40(2):e181-e186. https://doi.org/10.1016%2Fj.jogc.2017.11.025
22. Bamford C, Bonorchis K, Ryan A, et al. Antimicrobial susceptibility patterns of Escherichia coli strains 
isolated from urine samples in South Africa from 2007 - 2011. S Afr J Epidemiol Infect 2012;27(2):46-52. 
https://doi.org/10.1080%2F10158782.2012.11441483
23. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment 
of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update. Clin Infect Dis 
2011;52(5):e103-e120. https://doi.org/10.1093%2Fcid%2Fciq257
24. Raz R, Kennes Y, Colodner R, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in 
the treatment of women with uncomplicated urinary tract infections, in a geographical area with a 
high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002;34(9):1165-1169. https://
doi.org/10.1086%2F339812
25. Mavromanolakis E, Maraki S, Samonis G, et al. Effect of norfloxacin, trimethoprim-sulfamethoxazole 
and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. J Chemother 
1997;9(3):203-207. https://doi.org/10.1179%2Fjoc.1997.9.3.203
26. Ezechi OC, Fasubaa OB, Dare FO. Antibiotic sensitivity patterns of microbial isolates from the urine 
of pregnant women with urinary tract infections. Trop J Obstet Gynaecol 2004;20(2):113-115. https://
doi.org/10.4314%2Ftjog.v20i2.14413
27. Assefa A, Asrat D, Woldeamanuel Y, et al. Bacterial profile and drug susceptibility pattern of urinary 
tract infection in pregnant women at Tikur Anbessa Specialized Hospital Addis Ababa, Ethiopia. 
Ethiop Med J 2008;46(3):227-235.
28. Clark CJ, Kennedy WA, Shortliffe LD. Urinary tract infection in children: When to worry. Urol Clin N Am 
2010;37(2):229-241. https://doi.org/10.1016%2Fj.ucl.2010.03.009
29. Dwyer PL, O’Reilly M. Recurrent urinary tract infection in the female. Curr Opin Obstet Gynecol 
2002;14(5):537-543. https://doi.org/10.1097%2F00001703-200210000-00016
30. Berard A, Santos F, Ferreira E, et al. Urinary tract infections during pregnancy. In: Tenke P, ed. Urinary 
Tract Infections, 2011:113-134. https://www.intechopen.com/books/urinary-tract-infections/urinary-
tract-infections-during-pregnancy (accessed 4 August 2020). 
31. Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment 
of uncomplicated cystitis in women: A randomized trial. JAMA 2005;293(8):949-955. https://doi.
org/10.1001%2Fjama.293.8.949
32. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database 
Syst Rev 2015;(8):CD000490. https://doi.org/10.1002/14651858.cd000490.pub3
33. Bar-Oz B, Moretti ME, Boskovic R, et al. The safety of quinolones – a meta-analysis of pregnancy 
outcomes. Eur J Obstet Gynaecol 2009;143(2):75-78. https://doi.org/10.1016%2Fj.ejogrb.2008.12.007
34. National Department of Health. Guidelines for Maternity Care in South Africa. A Manual for Clinics, 
Community Health Centres and District Hospitals. 4th ed. Pretoria: NDoH, 2015:172.
35. Kasahara K, Baltus AJ, Lee SH, Edelstein MA, Edelstein PH. Prevalence of non-penicillin-susceptible 
group B streptococcus in Philadelphia and specificity of penicillin resistance screening methods. J Clin 
Microbiol 2010;48(4):1468-1469. https://doi.org/10.1128%2Fjcm.02296-09
36. Bolukaoto JY, Monyama CM, Chukwu MO, et al. Antibiotic resistance of Streptococcus agalactiae 
isolated from pregnant women in Garankuwa, South Africa. BMC Res Notes 2015;8:364. https://doi.
org/10.1186%2Fs13104-015-1328-0
37. Abdulla FE, Abdulla EM. Antibiotic options for Enterococcus faecalis infections. Pak J Med Sci 
2006;22(3):286-290.
Accepted 30 March 2020.
